NCT03226197

Brief Summary

Every year, efforts are made to resuscitate about 30,000 people when their hearts stop outside of the hospital environment ('out-of-hospital cardiac arrest'). Early damage to the brain due to 'oxygen starvation' (seemingly paradoxically) gets worse when blood flow is restored. Of the 6,350 survivors admitted to intensive care units, 46% die from brain damage, and half of those who survive suffer long-term brain damage. Apart from avoiding a high temperature, nothing has been found which can protect the brain or improve outcome. 'Ketones' are chemicals naturally produced in the body from fat during starvation. They act as an energy source, but also as regulators of metabolism, and appear to protect cells from damage when oxygen supplies are scarce, or when blood flow is restored. The investigators want to see whether a ketone drink will protect the brain after out-of-hospital cardiac arrest. The investigators will study 10 cardiac arrest patients, and participants will be given the ketone drink via a feeding tube (which is routinely passed into the stomach in such cases). The investigators shall check that the drink is absorbed, and measure the ketone levels in the blood. The investigators will also measure important aspects of blood chemistry (including pH and blood sugar) and collect data on brain (electrical recordings called 'EEG' and 'SSEP') and heart function (ultrasound scans or 'echocardiographs') - both of which it is hoped might improve - in order to demonstrate that this is possible if it is to be included in a subsequent large trial. The study will be scrutinised by world experts in the field, who have also helped design the study. If this pilot study is a success, the investigators will apply to a major grant body to fund an appropriately-powered randomised controlled trial to determine whether ketones improve neurological outcome and survival in these patients. Results will also allow similar studies to be planned in heart attack, stroke and traumatic brain injury.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
5

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2018

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 12, 2017

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 21, 2017

Completed
8 months until next milestone

Study Start

First participant enrolled

March 14, 2018

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 13, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 13, 2019

Completed
Last Updated

May 14, 2025

Status Verified

May 1, 2025

Enrollment Period

1.5 years

First QC Date

July 12, 2017

Last Update Submit

May 9, 2025

Conditions

Outcome Measures

Primary Outcomes (11)

  • Change from baseline arterial blood gas values for pH

    48 hours

  • Change from baseline arterial blood gas value for bicarbonate (mmol/L),

    48 hours

  • Change from baseline arterial blood gas value for base excess (mEq/L),

    48 hours

  • Change from baseline arterial blood gas value for glucose (mmol/L)

    48 hours

  • Change from baseline arterial blood gas value for lactate (mmol/L)

    48 hours

  • Change from baseline biochemistry laboratory results (full biochemistry panel including lipids, non-esterified fatty acids and serum insulin as per study protocol)

    48 hours

  • Change from baseline haematology laboratory results (full blood count and coagulation profile as per study protocol)

    48 hours

  • Time from arrival of participant to ketone drink administration (hh:mm)

    24 hours

  • Number of participants receiving full course of ketone drink

    As defined in study protocol: 25ml bolus followed after 1 hour by 47 hour infusion at 6 ml per hour

    48 hours

  • Change from baseline serum troponin (ng/ml)

    12 hours

  • Change from baseline serum neuron specific enolase (ng/ml)

    48 hours

Secondary Outcomes (4)

  • Change from baseline level of plasma betahydroxybutyrate (mmol/L)

    48 hours

  • Number of participants undergoing electroencephalogram as per protocol

    72 hours

  • Number of participants undergoing somatosensory evokes potentials as per protocol

    72 hours

  • Number of participants undergoing echocardiography as per protocol

    72 hours

Study Arms (1)

Study group

EXPERIMENTAL

Ketone ester drink to be administered by nasogastric tube. Initial bolus dose of 25 ml on enrollment. After 1 hour, begin 47 hr infusion at 6 ml per hour.

Dietary Supplement: Ketone ester drink

Interventions

Ketone ester drinkDIETARY_SUPPLEMENT

Ketone ester drink

Study group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18 years or above
  • Male or female
  • Comatose survivors of out-of-hospital cardiac arrest, defined as return of spontaneous circulation for at least 5 minutes with a score of \<8 on the Glasgow Coma Scale
  • For admission to intensive care unit for full, active treatment

You may not qualify if:

  • Primary neurological or intracranial cause of cardiac arrest
  • In-hospital cardiac arrest
  • Over 4 hours from time of return of spontaneous circulation to enrollment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Barts Heart Centre

London, United Kingdom

Location

MeSH Terms

Conditions

Out-of-Hospital Cardiac Arrest

Condition Hierarchy (Ancestors)

Heart ArrestHeart DiseasesCardiovascular Diseases

Study Officials

  • Ajay Jain, MBBS MD

    Consultant Cardiologist

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 12, 2017

First Posted

July 21, 2017

Study Start

March 14, 2018

Primary Completion

September 13, 2019

Study Completion

September 13, 2019

Last Updated

May 14, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations